Vertex gets reimbursement deal for Orkambi in Sweden

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) said Monday it agreed to a long-term access agreement for cystic fibrosis drug Orkambi lumacaftor/ivacaftor with Swedish authorities. Beginning

Read the full 237 word article

User Sign In